Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

NCT06121232 · clinicaltrials.gov ↗

NA

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Neuropathy;Peripheral

Interventions

DEVICE: Abbott® DRG / Abbott®/Medtronic® SCS
OTHER: Control Group

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]